American Society of Addiction Medicine
American Society of Addiction Medicine
The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients
The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients
The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients
Monday 4th November 2024
Dr. Joji Suzuki discusses the promise of GLP-1 agonists in treating substance use disorders and shares insights from his extensive career in addiction psychiatry.
24 minutes
Informative
Hopeful
Educational
Supportive
Engaging
About this podcast
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Navigating Intimate Relationships
Nutritional Pathways to Recovery
Links:
Visit site
Episodes:
35 (View all)
Do you want to link to this podcast?
Get the buttons here!Unlocking the Potential of GLP-1 Agonists in Addiction Treatment
Episode Overview
- GLP-1 agonists show promise in reducing alcohol and tobacco use.
- More research is needed before recommending GLP-1s for substance use disorders.
- An interdisciplinary approach is crucial in addiction medicine.
- New therapies are desperately needed to improve addiction treatment.
- Hospital-based consultants play a vital role in addressing substance use in medical settings.
We are long overdue for better treatments, and GLP-1s represent one of those potential new options.
Ever wondered about the potential of GLP-1 agonists in treating substance use disorders? In this episode of Addiction Medicine: Beyond the Abstract, Dr. Joji Suzuki joins host Dr. Shawn McNeil to discuss his recent review on this very topic. Dr. Suzuki, a prominent figure in addiction psychiatry at Brigham and Women’s Hospital and Harvard Medical School, shares his journey from a chemistry major fascinated by neurotransmitters to a leading addiction consultant.
His career has been shaped by the opioid crisis and his desire to make a difference in addiction treatment. He highlights the unexpected benefits of GLP-1 agonists, initially used for diabetes and obesity, which have shown promise in reducing alcohol and tobacco use. However, he advises caution, noting that more research is needed before these medications can be widely recommended for substance use disorders. Dr.
Suzuki also discusses the importance of an interdisciplinary approach in addiction medicine and the need for new therapies. This episode is a must-listen for anyone interested in the evolving landscape of addiction treatment and the potential role of GLP-1 agonists.